IMMUNOCLIN CORP (IMCL)

0.16
OTC Markets
Prev Close 0.16
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.10 / 0.19
Exchange OTC Markets
Shares Outstanding 28.83B
Market Cap 4.58M
Div & Yield N.A. (N.A)
ImClone: Mystery Suitor to Decide This Week

ImClone: Mystery Suitor to Decide This Week

The company says it will divulge the suitor's name should the offer be withdrawn.

Stock Futures Sharply Lower Ahead of Bailout Vote

Stock Futures Sharply Lower Ahead of Bailout Vote

As the government's banking-sector bailout faces a vote in the House of Representatives and in the Senate later in the week, investors absorb news of Citi's takeover of Wachovia.

U.S. Stocks Set to Open Lower Monday

U.S. Stocks Set to Open Lower Monday

Congress was finalizing the government's bailout proposal of financial institutions. The House of Representatives is expected to vote on the bill Monday, and the Senate would follow suit later in the week.

ImClone Continues Talks for Sale: Report

ImClone Continues Talks for Sale: Report

ImClone last week dismissed Bristol-Myers Squibb's hostile tender offer of $62 a share.

'Fast Money' Recap: Gaming Goldman

'Fast Money' Recap: Gaming Goldman

The trading panel ponders the prospects for the star investment bank.

Icahn Dismisses Bristol's Higher ImClone Bid (Update2)

Icahn Dismisses Bristol's Higher ImClone Bid (Update2)

The company finds another $2 a share to sweeten the deal.

Stocks Close Uneven Day With Losses

Stocks Close Uneven Day With Losses

The Fed and Treasury heads testify before Congress regard the proposed the $700 billion, financial-firm rescue plan.

Health Winners & Losers: ImClone

Bristol-Myers increased its bid for ImClone, but health care stocks struggled for direction on Tuesday.

Stocks Slip on Recession Remarks

The Fed and Treasury heads testify before Congress regard the proposed the $700 billion, financial-firm rescue plan.

Stocks Hold Ground on Bailout Testimony

The Fed and Treasury heads testify before Congress regard the proposed the $700 billion, financial-firm rescue plan.

Stocks Build on Gains

But fear remains that the $700 billion bailout of financial firms will drive up interest rates and weaken the dollar.

Stock Futures Hint at Down Open for U.S.

Investor fear remains that the $700 billion bailout of financial firms will drive up interest rates and weaken the dollar.

Feuerstein's Biotech Mailbag: ImClone

Feuerstein's Biotech Mailbag: ImClone

Understandig the drug-rights fight between ImClone and Bristol. What about Sangamo's drug for treating diabetic nerve damage? And a big fat zero for Mannkind.

Health Winners & Losers: Amgen

Health Winners & Losers: Amgen

Amgen gains on positive denosumab study results.

Health Winners & Losers: Gilead

Gilead shares drop despite nods from analysts. Bristol trades up, and ImClone falls as merger talk continues.

Bristol, ImClone Dispute Rights (Update)

Bristol, ImClone Dispute Rights (Update)

Bristol-Myers Squibb says it will not raise its bid for ImClone, raising a point of contention that could impact a sale to another bidder.

Health Winners & Losers: Bristol, ImClone

Health Winners & Losers: Bristol, ImClone

Bristol and ImClone shares fall as more drama unfolds surrounding their potential merger. King Pharmaceuticals' shares are down after it increased its bid for Alpharma.

King Gets Hostile With Alpharma (Update)

King Gets Hostile With Alpharma (Update)

King Pharmaceuticals took its rejected $37-a-share offer directly to Alpharma shareholders Thursday.

King Gets Hostile With Alpharma

King Gets Hostile With Alpharma

King Pharmaceuticals took its rejected $37-a-share offer directly to Alpharma shareholders Thursday.

ImClone's Erbitux Prolongs Survival: Study

ImClone's Erbitux Prolongs Survival: Study

Results of a study show that adding Erbitux to a platinum-based chemotherapy in the first-line treatment of the cancer resulted in statistically significant improvement in the primary endpoint of overall survival.

'Fast Money' Recap: Lost on Lehman

'Fast Money' Recap: Lost on Lehman

The trading panel says the troubled investment bank offered no clarity.

Health Winners & Losers: ImClone

Health Winners & Losers: ImClone

ImClone said an undisclosed company offered $70 a share for the company, as it officially passed on Bristol-Myers' lower bid.

Stocks Edge Higher Despite Lehman Woes

Stocks Edge Higher Despite Lehman Woes

Frank Curzio's guests include Jim Cramer and Gregg Greenberg.

Stocks End Volatile Day With Modest Gains

Stocks End Volatile Day With Modest Gains

The major indices shake off a wobbly start to end in the green. Lehman's new plans dominate investor interest. See Frank Curzio's take in The Real Story (above).

Stocks Holding to Moderate Gains

Stocks Holding to Moderate Gains

The major indices reflect volatile trading but continue to hold to afternoon gains as investors weigh Lehman's restructuring plan and other news.

ImClone Gets Better offer, Rejects Bristol

ImClone Gets Better offer, Rejects Bristol

ImClone says an unnamed bidder has topped Bristol-Myers' $60-a-share offer by $10 a share.

Stocks Build Modest Gains

Stocks Build Modest Gains

The major indices reflect volatile trading as investors weigh Lehman's restructuring plan against other news.

ImClone Gets Better Offer, Rejects Bristol

ImClone says an unnamed bidder has topped Bristol-Myers' $60-a-share offer by $10 a share.

ImClone Receives New $70-a-Share Bid

ImClone says an unnamed bidder has topped Bristol-Myers' $60-a-share offer by $10 a share.

'Fast Money' Recap: Gaming the Fannie Plan

'Fast Money' Recap: Gaming the Fannie Plan

The trading panel discusses what the Treasury plan means for Fannie and Freddie.